Imithi eSebenza ixesha elide kwizifo ze-Parkinson
Ukulawulwa kwesifo sika-Parkinson asikho ubunzima bayo. Iyeza levodopa / carbidopa (eyaziwa ngokuba yiSinemet) isabonwa njengenyango yegolide yegolide yeempawu zempawu zesi sifo. Kodwa kunikwe into yokuba iSinemet isebenza ngokufutshane, kukho ixesha phakathi kwamanani apho iimpawu zibuyela kwakhona njengoko amanqanaba eziyobisi ehla. Kwaye njengoko isifo sifana, le nyanga ayisebenzisekanga kangako ekulawuleni iimpawu zokuqhubela phambili.
Izigulane zifuna ukuthatha amanyathelo athile rhoqo kwizame zokuphepha "ixesha eliphumayo" apho iziphumo zonyango ziphela.
Indlela eya kunceda ngayo iya kuba yinto eyenza i-levodopa / carbidopa ihambe ngokuthe ngcembe, inika amazinga amanqanaba amachiza kunye nokunciphisa ukuguqulwa kweempawu. Oku kuya kuthetha ukuba "ngaphantsi kwexesha" kwiigulane zikaParkinson.
Ingaba isebenza kanjani
I-Rytary ivunywe kunyango lwe-Parkinson. Inhlobo ye-capsule yomlomo evuliwe ngokubanzi ye-carbidopa / levodopa, inhlanganisela yeziyobisi esetyenziselwe amashumi eminyaka kwifom yokukhuphela kwayo (eyaziwa ngokuqhelekileyo ngegama legama, iSinemet). Ngokungafani nongaphambili kwayo, kunye neRytary, zombini amanqanaba afanelekileyo kwaye anwetshiwe we-carbidopa / levodopa atholakala egazini emva kwesilinganiso esisodwa.
Ukuvunyelwa kwesi siza kwavela emva kweziphumo zezilingo ezimbini ezinkulu zeklinikhi. Eyokuqala, i-APEX-PD yayisifundo esenziwe kakuhle (i-randomized, i-blind-blinded, i-placebo-elawulwayo) apho izigulane ezingama-381 ezineentsholongwane zakuqala zePasinson zifumene esinye sezifo ezintathu ezichanekileyo zezilwanyana okanye i-placebo kwiiveki ezingama-30.
Iziphumo zabonisa ukuphucula kwezo zombini izakhono, umsebenzi wokuphila kwansuku zonke kunye nomgangatho wobomi bokuphela.
Ukuhlukana nokufunda okokuqala, isilingo sesibini kwikliniki, izifundo ezibhalwe kwi-ADVANCE-PD ezibhalwe zizifo eziphambili eziye zafumana ukutshintshwa kweemoto okanye "ixesha elide." Izigulane ezingama-393 zazingenakulinganiswa ukuba zithole iRytary okanye i-carbidopa-levodopa, ngokukhawuleza.
Abo bafumana amachiza amatsha babephantsi kakhulu "kwixesha," kubangele "ngexesha" ngaphandle kweedyskinesias xa kuthelekiswa nalabo bafumana unyango lwabo oluqhelekileyo olukhutshwa ngokukhawuleza.
Yintoni eyenza iRytary Better?
I-Rytary ayiyilungiselelo lokuqala lokukhululwa. I-Stalevo (equkethe i-levodopa, i-carbidopa, kunye ne-entacapone) sele ikhona kwimarike ukususela kwaye isebenza kakuhle kwizigulane ezininzi. Yintoni eyenza ukuba lolu hlobo olutsha lube ngcono?
Ukuvunyelwa kwe-FDA ye-RYTARY (i-rye-rye-TAR-ee) ebizwa ngokuba yintlupheko ebalulekileyo yokunyanga kwesifo se-Parkinson kwaye inika imveliso ye-carbidopa-levodopa ekhutshwa ngokubanzi eyenza isifo seParkinson, "utshilo uFred Wilkinson, umongameli kunye ne-CEO, Impax IiWateratories. "I-RYTARY yenzelwe ukujongana nesinye sezidingo ezibalulekileyo ezingapheliyo kwizigulana eziphila nesifo sika-Parkinson, okukunciphisa inani lexesha ngelixa iimpawu zabo zingalawulwa ngokwaneleyo."
Nangona kungengeyonyango esikulindeleyo, iRytary inika esinye isidakamizwa kwibhokisi yeetekisi. Ugqirha wakho uya kukwazi ukunquma ukuba okanye akufanele yini ukuyisebenzisa ekulawuleni kwesifo sakho okanye ukuba elinye iyeza linika iziphumo ezingcono.
Imithombo:
Beck, James, MD. "Ividiyo: I-FDA ivumela i-RYTARY &." Ividiyo: I-FDA iyavuma i-RYTARY & . I-Parkinson's Disease Foundation, 08 Jan. 2015.Webhu.
"I-Impax Pharmaceuticals Ivakalisa i-FDA imvume ye-RYTARY ™ (i-Carbidopa kunye ne-Levodopa) i-Caps-Release Release Capsules yokuPhathwa kwezifo ze-Parkinson." I-Impax Pharmaceuticals Ivakalisa i-FDA imvume ye-RYTARY ™ (i-Carbidopa kunye ne-Levodopa) I-Capsules- Export -Release Release ... Impax Laboratories Inc., ngomhla ka-08 Januwari 2015. IWebhu.